Javascript must be enabled to continue!
Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas
View through CrossRef
AbstractRas signaling is important for the intracellular transduction of mitogenic stimuli from activated growth factor receptors. We have investigated 37 sporadic malignant melanomas (15 primary cutaneous melanomas and 22 melanoma metastases) and 6 melanoma cell lines for mutations in the 3 Ras genes NRAS, KRAS and HRAS. All tumors and cell lines were additionally analyzed for mutation and expression of BRAF, which encodes a Ras‐regulated serine/threonine kinase with oncogenic properties, as well as for expression of RASSF1A, which encodes a Ras‐binding protein with tumor suppressor properties. Mutational analyses identified somatic NRAS mutations in 2 primary melanomas, 4 melanoma metastases and 2 cell lines. One melanoma metastasis showed a somatic KRAS mutation whereas HRAS mutations were not detected. Eight primary melanomas, 6 melanoma metastases and 4 melanoma cell lines carried BRAF mutations affecting the known hot‐spot codon 599. None of the tumors or cell lines with BRAF mutation demonstrated NRAS or KRAS mutations. Real‐time reverse transcription‐PCR showed that 8 melanomas (3 primary tumors, 5 melanoma metastases) had reduced RASSF1A transcript levels of ≤50% relative to benign melanocytic nevi and normal skin. Three melanoma cell lines lacked detectable RASSF1A transcripts. The RASSF1A gene promoter was hypermethylated in these 3 cell lines as well as in 6 of 8 melanomas with reduced RASSF1A mRNA levels. Treatment of the cell lines with 5‐aza‐2′‐deoxycytidine and trichostatin A resulted in demethylation of the RASSF1A promoter and re‐expression of RASSF1A transcripts. Most tumors and all cell lines with RASSF1A promoter methylation additionally carried BRAF or NRAS mutations, suggesting a synergistic effect of these aberrations on melanoma growth. Taken together, 57% of the investigated melanomas and 100% of the melanoma cell lines carried mutations in either NRAS, KRAS or BRAF. In addition, 22% of the melanomas and 50% of the cell lines showed reduced RASSF1A transcript levels. Thus, alterations of Ras pathway genes are of paramount importance in the pathogenesis of sporadic melanomas. © 2004 Wiley‐Liss, Inc.
Title: Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas
Description:
AbstractRas signaling is important for the intracellular transduction of mitogenic stimuli from activated growth factor receptors.
We have investigated 37 sporadic malignant melanomas (15 primary cutaneous melanomas and 22 melanoma metastases) and 6 melanoma cell lines for mutations in the 3 Ras genes NRAS, KRAS and HRAS.
All tumors and cell lines were additionally analyzed for mutation and expression of BRAF, which encodes a Ras‐regulated serine/threonine kinase with oncogenic properties, as well as for expression of RASSF1A, which encodes a Ras‐binding protein with tumor suppressor properties.
Mutational analyses identified somatic NRAS mutations in 2 primary melanomas, 4 melanoma metastases and 2 cell lines.
One melanoma metastasis showed a somatic KRAS mutation whereas HRAS mutations were not detected.
Eight primary melanomas, 6 melanoma metastases and 4 melanoma cell lines carried BRAF mutations affecting the known hot‐spot codon 599.
None of the tumors or cell lines with BRAF mutation demonstrated NRAS or KRAS mutations.
Real‐time reverse transcription‐PCR showed that 8 melanomas (3 primary tumors, 5 melanoma metastases) had reduced RASSF1A transcript levels of ≤50% relative to benign melanocytic nevi and normal skin.
Three melanoma cell lines lacked detectable RASSF1A transcripts.
The RASSF1A gene promoter was hypermethylated in these 3 cell lines as well as in 6 of 8 melanomas with reduced RASSF1A mRNA levels.
Treatment of the cell lines with 5‐aza‐2′‐deoxycytidine and trichostatin A resulted in demethylation of the RASSF1A promoter and re‐expression of RASSF1A transcripts.
Most tumors and all cell lines with RASSF1A promoter methylation additionally carried BRAF or NRAS mutations, suggesting a synergistic effect of these aberrations on melanoma growth.
Taken together, 57% of the investigated melanomas and 100% of the melanoma cell lines carried mutations in either NRAS, KRAS or BRAF.
In addition, 22% of the melanomas and 50% of the cell lines showed reduced RASSF1A transcript levels.
Thus, alterations of Ras pathway genes are of paramount importance in the pathogenesis of sporadic melanomas.
© 2004 Wiley‐Liss, Inc.
Related Results
CLIMATE-2019 Program committee
CLIMATE-2019 Program committee
NOTITLE. Chairman
Mokhov Igor
RAS academecian, Dr. Sci., Professor
...
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Are Cervical Ribs Indicators of Childhood Cancer? A Narrative Review
Abstract
A cervical rib (CR), also known as a supernumerary or extra rib, is an additional rib that forms above the first rib, resulting from the overgrowth of the transverse proce...
Identification of microRNA-Regulated Pathways through a Integration of Mcrorna-mRNA Microarray and Bioinformatics Analysis in CD34+ Cells of Myelodysplastic Syndromes
Identification of microRNA-Regulated Pathways through a Integration of Mcrorna-mRNA Microarray and Bioinformatics Analysis in CD34+ Cells of Myelodysplastic Syndromes
Abstract
Background
MicroRNAs (miRNAs) are considered to play a key role in the pathogenesis of myelodysplastic syndromes (MDS). However, the effect o...
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Clinicopathological Features of Indeterminate Thyroid Nodules: A Single-center Cross-sectional Study
Abstract
Introduction
Due to indeterminate cytology, Bethesda III is the most controversial category within the Bethesda System for Reporting Thyroid Cytopathology. This study exam...
Abstract 920: COP1 E3 ligase regulates response to oncogenic MAPK pathway inhibition
Abstract 920: COP1 E3 ligase regulates response to oncogenic MAPK pathway inhibition
Abstract
Oncogenically activated RAS-MAPK pathway is the driver of several cancers including the majority of non-small cell lung adenocarcinomas (NSCLC). RAS-MAPK pa...
Abstract A31: Targeting Oncogenic Ras Activation for Cancer Prevention
Abstract A31: Targeting Oncogenic Ras Activation for Cancer Prevention
Abstract
Increased Ras activity levels due to active mutations of Ras are critical for tumorigenesis. These oncogenic Ras mutations are considered to be locked in a ...
Abstract 5197: Comparative proteome analysis reveals flotillin-1 as an H-Ras-interacting lipid raft protein critical for breast epithelial cell invasion
Abstract 5197: Comparative proteome analysis reveals flotillin-1 as an H-Ras-interacting lipid raft protein critical for breast epithelial cell invasion
Abstract
Metastatic spread is the major cause of death from breast cancer. The objective of our study is to unveil signal transduction pathways specific to breast ep...
Plasma biomarkers to predict clinical outcomes of FOLFIRI plus ramucirumab (RAM) as second-line treatment for RAS wild-type metastatic colorectal cancer: JACCRO CC-16AR.
Plasma biomarkers to predict clinical outcomes of FOLFIRI plus ramucirumab (RAM) as second-line treatment for RAS wild-type metastatic colorectal cancer: JACCRO CC-16AR.
177 Background: Angiogenesis-factors (AFs) have been reported as prognostic biomarkers for metastatic colorectal cancer (mCRC). RAS status in circulating-tumor DNA (ctDNA) is cons...

